
Publication
Prosecuting AI-related patents in China
AI technology is flourishing in China, leading to a surge in innovators seeking to protect their intellectual property.
Canada | Publication | July 16, 2020
In this legal update and in a forthcoming legal update, we will be addressing two proposed regulations published by the Office des professions du Québec. These proposed regulations are part of several legislative initiatives aimed at granting pharmacists greater professional autonomy and at broadening the scope of the professional acts they are permitted to perform.
In particular, the Regulation respecting certain professional activities that may be engaged in by a pharmacist proposes to broaden the conditions under which pharmacists will be able to prescribe, adjust or stop certain medications.
The Règlement sur l’amorce et la modification d’une thérapie médicamenteuse, sur l’administration d’un médicament et sur la prescription de tests par un pharmacien (Regulation respecting the initiation and amendment of a drug therapy, the administration of a drug and the prescribing of tests by a pharmacist) includes the following amendments to the current regulations:
For more information, please contact us, consult our blog or the Regulation respecting certain professional activities that may be engaged in by a pharmacist and the Règlement sur l’amorce et la modification d’une thérapie médicamenteuse, sur l’administration d’un médicament et sur la prescription de tests par un pharmacien.
The Office des professions du Québec invites those interested to submit comments on the proposed regulations before July 27, 2020. The address to be used to send comments or to obtain additional information about the proposed regulations is published in the Gazette officielle du Québec. You can also contact us for assistance in presenting your comments.
Publication
AI technology is flourishing in China, leading to a surge in innovators seeking to protect their intellectual property.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025